Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Comparison of Two Heart Attack Drugs Fails to Prove Primary Endpoint SOUTH SAN FRANCISCO, Calif. -- March 17, 1997 -- Results from the GUSTO III study, announced at the American College of Cardiology annual meeting, demonstrated that a new thrombolytic agent, Retavase(R) (reteplase) does not save more lives than Activase(R) (alteplase). Activase is a recombinant tissue plasminogen activator, t-PA, indicated for the treatment of acute myocardial infarction (AMI). Investigators of the GUSTO group reported that in the trial, Retavase, a thrombolytic marketed by Boehringer Mannheim, did not provide a statistically significant benefit in 30-day mortality as compared to Activase. In the trial, 10,139 patients received Retavase while 4,921 patients were given Activase. Genentech Vice President of Clinical Research, David Stump, MD, commented on the trial. "The primary hypothesis, as established by the investigators, was to determine if Retavase would save more lives than Activase. Since this primary hypothesis was not proven, Activase remains a standard of care in the management of AMI. We believe there is no reason for physicians to change their prescribing habits." The overall mortality rate for Retavase was 7.43% as compared to 7.22% with Activase. Total intracranial hemorrhage rate for Retavase was 0.91% and 0.88% for Activase. Total stroke rates were 1.67% and 1.83%, respectively. "For the past 10 years, physicians have used Activase to save the lives of heart attack patients. In 1996, Activase was also the first therapy cleared by the U.S. Food & Drug Administration for the treatment of acute ischemic stroke. Its importance to cardiovascular medicine is enormous and GUSTO III reinforces the role Activase plays in saving lives every day," Dr. Stump said. Genentech, Inc. is a biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals. E-mail this page to a friend or colleague! To print, use this version